Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Animals
Carcinoma, Renal Cell
/ metabolism
Cell Line, Tumor
E1A-Associated p300 Protein
/ metabolism
Female
GTP-Binding Proteins
/ metabolism
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
/ metabolism
Kidney Neoplasms
/ metabolism
Mice, Inbred BALB C
Mice, Nude
Neovascularization, Pathologic
/ metabolism
Protein Glutamine gamma Glutamyltransferase 2
Protein Interaction Maps
Transglutaminases
/ metabolism
Tumor Suppressor Protein p53
/ metabolism
HIF-1α
angiogenesis
p53
renal cell carcinoma
transglutaminase 2
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Jul 2020
17 Jul 2020
Historique:
received:
28
05
2020
revised:
04
07
2020
accepted:
15
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Angiogenesis and the expression of vascular endothelial growth factor (VEGF) are increased in renal cell carcinoma (RCC). Transglutaminase 2 (TGase 2), which promotes angiogenesis in endothelial cells during wound healing, is upregulated in RCC. Tumor angiogenesis involves three domains: cancer cells, the extracellular matrix, and endothelial cells. TGase 2 stabilizes VEGF in the extracellular matrix and promotes VEGFR-2 nuclear translocation in endothelial cells. However, the role of TGase 2 in angiogenesis in the cancer cell domain remains unclear. Hypoxia-inducible factor (HIF)-1α-mediated VEGF production underlies the induction of angiogenesis in cancer cells. In this study, we show that p53 downregulated HIF-1α in RCC, and p53 overexpression decreased VEGF production. Increased TGase 2 promoted angiogenesis by inducing p53 degradation, leading to the activation of HIF-1α. The interaction of HIF-1α and p53 with the cofactor p300 is required for stable transcriptional activation. We found that TGase 2-mediated p53 depletion increased the availability of p300 for HIF-1α-p300 binding. A preclinical xenograft model suggested that TGase 2 inhibition can reverse angiogenesis in RCC.
Identifiants
pubmed: 32708896
pii: ijms21145042
doi: 10.3390/ijms21145042
pmc: PMC7404067
pii:
doi:
Substances chimiques
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Tumor Suppressor Protein p53
0
E1A-Associated p300 Protein
EC 2.3.1.48
EP300 protein, human
EC 2.3.1.48
Protein Glutamine gamma Glutamyltransferase 2
EC 2.3.2.13
Transglutaminases
EC 2.3.2.13
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Cancer Center
ID : 1910060-2
Pays : Republic of Korea
Références
Genes Dev. 2000 Jan 1;14(1):34-44
pubmed: 10640274
J Urol. 1997 Apr;157(4):1482-6
pubmed: 9120987
Biochem J. 2004 May 15;380(Pt 1):289-95
pubmed: 14992692
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
Cell Death Dis. 2016 Mar 31;7:e2163
pubmed: 27031960
J Cancer Res Clin Oncol. 2014 May;140(5):757-67
pubmed: 24610445
Cancers (Basel). 2018 Nov 19;10(11):
pubmed: 30463244
Biomol Ther (Seoul). 2019 Jan 31;27(1):34-40
pubmed: 30231606
J Biol Chem. 2005 Jun 24;280(25):23675-83
pubmed: 15849356
Science. 1987 Jan 23;235(4787):442-7
pubmed: 2432664
Biochem J. 2010 Apr 14;427(3):467-75
pubmed: 20156196
Exp Cell Res. 2006 Oct 1;312(16):2973-82
pubmed: 16914140
Nat Commun. 2017 Feb 16;8:14450
pubmed: 28205552
Genes Dev. 1995 Sep 1;9(17):2170-83
pubmed: 7657168
Cell Death Dis. 2016 Apr 21;7:e2200
pubmed: 27100894
Mol Cell. 2001 Apr;7(4):811-22
pubmed: 11336704
J Biol Chem. 2015 Aug 28;290(35):21365-75
pubmed: 26160175
Cancer Res. 1994 Aug 1;54(15):4233-7
pubmed: 7518352
Nature. 1997 Jun 19;387(6635):819-23
pubmed: 9194564
Adv Enzymol Relat Areas Mol Biol. 1983;54:1-56
pubmed: 6133417
Cancer. 1976 Dec;38(6):2469-80
pubmed: 1000477
FASEB J. 1999 Oct;13(13):1787-95
pubmed: 10506581
Nature. 1997 Jun 19;387(6635):823-7
pubmed: 9194565
Gut. 2003 Feb;52(2):159-61
pubmed: 12524388
Amino Acids. 2017 Mar;49(3):489-500
pubmed: 27394141
FASEB J. 2013 Sep;27(9):3487-95
pubmed: 23704086
Trends Biochem Sci. 2015 Aug;40(8):425-34
pubmed: 26032560
J Biol Chem. 1998 May 15;273(20):11995-8
pubmed: 9575138
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73
pubmed: 8917528
FASEB J. 2019 Feb;33(2):2327-2342
pubmed: 30285580
Biol Reprod. 2013 Oct 17;89(4):88
pubmed: 23966323
J Pathol Transl Med. 2015 Jan;49(1):37-43
pubmed: 25812656
Nat Med. 1997 Jul;3(7):797-801
pubmed: 9212111
Int J Mol Sci. 2020 Apr 03;21(7):
pubmed: 32260198
J Biol Chem. 2009 Aug 14;284(33):22041-7
pubmed: 19542224
World J Urol. 2015 Oct;33(10):1553-60
pubmed: 25515319
Cancer Res. 2005 May 15;65(10):3967-79
pubmed: 15899784